Roflumilast CAS 162401-32-3 Assay 99.0~101.0% API

Short Description:

Chemical Name: Roflumilast

CAS: 162401-32-3

Assay: 99.0~101.0% (Calculated on Dried Basis)

Appearance: White or Almost White Crystalline Powder

API PDE-4 Inhibitor COPD

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Roflumilast Intermediates:
Roflumilast CAS 162401-32-3
4-Amino-3,5-Dichloropyridine CAS 22889-78-7

Chemical Properties:

Chemical Name	Roflumilast
Synonyms	3-(Cyclopropylmethoxy)-N-(3,5-Dichloropyridin-4-yl)-4-(Ddifluoromethoxy)benzamide
CAS Number	162401-32-3
CAT Number	RF-PI2075
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C17H14Cl2F2N2O3
Molecular Weight	403.21
Density	1.471±0.060 g/cm3
Sensitivity	Heat Sensitive
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White or Almost White Crystalline Powder
Solubility	Free soluble in acetone, sparingly soluble in acetronitrile, slightly insoluble in anhydrous ethanol, practically insoluble in water
Melting Point	157.0~162.0℃
Loss on Drying	<0.50%
Residue on Ignition	≤0.10%
Heavy Metals	≤10ppm
Chloride	≤0.01%
Identification A. UV	The wavelength of maximum absorption should be at 213~251nm
Identification B. IR	The IR absorption spectrum of sample corresponds to that of the reference one
Identification C.	It shows the reaction of Fluoride
Related Substances
Single Impurity	≤0.10%
Total Impurities	<0.50%
Residual Solvents
Tert-Butanol	<0.10%
Tetrahydrofuran	<0.072%
Toluene	<0.089%
N,N-Dimethylformamide	<0.088%
Assay	99.0~101.0% (Calculated on Dried Basis)
Test Standard	Enterprise Standard
Usage	API; COPD

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

Roflumilast (CAS: 162401-32-3) is a selective oral phosphodiesterase-4 (PDE-4) inhibitor and a benzamide compound. It was developed by the German company Altana in 1993 and is the only oral PDE-4 inhibitor used to treat respiratory tract diseases approved for sale. Roflumilast is the first drug of its kind to target severe chronic obstructive pulmonary disease (COPD), and it is also the first oral anti-inflammation drug specifically developed for COPD patients. Its unique properties can help regulate COPD: when used in combination with bronchodilators to treat extremely severe COPD patients, Roflumilast can has the advantage of further reducing symptoms and deterioration rate, thus making it the first drug that targets patients with recurring deteriorating phenotype-spAecific COPD and severe air flow obstruction related to chronic coughing and excess phlegm. Besides being a treatment for severe COPD, Roflumilast can also be used to prevent and treat livestock respiratory tract diseases, excess mucosa bronchitis cough, asthmatic bronchitis, and acute bronchitis and air sacculitis accompanied by abnormal respiratory tract secretion.